Transaction|March 25, 2015
SteadyMed announces closing of initial public offering
Torys acted as U.S. counsel to the syndicate of underwriters led by Wells Fargo Securities and RBC Capital Markets with a team that included Cheryl Reicin, Mile Kurta, Erin Wiley and Miranda Callaghan (corporate/securities), David Mattingly and Jonathan Weinblatt (tax), Karen Townsend and Ed Fan (IP).
On March 25, 2015, SteadyMed Ltd. (SteadyMed) announced the closing of its initial public offering of 4,700,000 ordinary shares at a price to the public of US$8.50 per share, resulting in gross proceeds of approximately US$40 million before underwriting discounts and commissions. Wells Fargo Securities, LLC and RBC Capital Markets, LLC acted as joint book‐running managers for the offering, while JMP Securities LLC acted as lead manager.
SteadyMed is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs.
Further information can be found on SteadyMed's website.